ARTICLES| VOLUME 397, ISSUE 10281, P1293-1300, APRIL 03, 2021 Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial Stéphane Gaudry, David Hajage, Laurent Martin-Lefevre, et al Lancet 2021; 397: 1293-1300 Summary Background Delaying renal replacement therapy (RRT) for some time in critically ill patients with severe acu...

Original Investigation May 6, 2021 Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers Yoel Angel, Avishay Spitzer, Oryan Henig, et al JAMA. Published online May 6, 2021. doi:10.1001/jama.2021.7152 Abstract Importance Randomized clinical trials have provided estimates of the effectiveness of the BNT162b2 vaccine against symptomatic SARS-CoV-2 infection,...

ARTICLES| VOLUME 397, ISSUE 10283, P1459-1469, APRIL 17, 2021 SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) Victoria Jane Hall, Sarah Foulkes, Andre Charlett, et al Lancet 2021; 379: 1459-1469 DOI:https://doi.org/10.1016/S0140-6736(21)00675-9 Summary Background Increased understanding of whether individuals who have r...

Improving Survival of Critical Care Patients With COVID-19 in England Data from the UK suggests that there has been an improvement in the survival of hospitalised patients with COVID-19 in recent months. Case-fatality rate of hospitalised patients declined from 6% in April 2020 to 1.5% by July 2020.  A possible explanation for this shift may be the fact that there has been a shift in the demographics of people admitted with COVID-19. Patients are now younger an...

CORRESPONDENCE|ONLINE FIRST Thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine: side-effect or coincidence? Søren Dinesen Østergaard, Morten Schmidt, Erzsébet Horváth-Puhó, et al Lancet Published: March 30, 2021 DOI:https://doi.org/10.1016/S0140-6736(21)00762-5 By mid March, 2021, vaccination against COVID-19 using the ChAdOx1 nCoV-19 (AZD1222) vaccine from Oxford–AstraZeneca1, 2was paused in a number of European countries due to reports of thrombo...

ORIGINAL ARTICLE A Microbiota-Directed Food Intervention for Undernourished Children Robert Y. Chen, Ishita Mostafa, Matthew C. Hibberd, et al N Engl J Med April 7, 2021DOI: 10.1056/NEJMoa2023294 BACKGROUND More than 30 million children worldwide have moderate acute malnutrition. Current treatments have limited effectiveness, and much remains unknown about the pathogenesis of this condition. Children with moderate acute malnutrition have perturbed developme...

ONLINE FIRST (FREE ACCESS)  Abraham P. et al. - Trauma patients do not benefit from a viscoelastic haemostatic assay-guided protocol, but why?MacDonald B. ~Fear and insight in the ICU bedChaudhuri D. et al. -  Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysisEvangelista I. et al. - Renal pyonephrosis with massive pleural empyema Cecconi M. et al. ~ Diversity and inclusivity...

EDITORIAL Effect of Oxygen Therapy on Mortality in the ICU Paul J. Young N Engl J Med 2021; 384:1361-1363DOI: 10.1056/NEJMe2101538 Oxygen therapy is a key component of supportive care for patients who have hypoxemic respiratory failure and are being treated in the intensive care unit (ICU). Yet, although oxygen can be lifesaving for patients with severe hypoxemia, overzealous oxygen administration may be harmful. Furthermore, data to inform the use of oxygen t...

COMMENT| VOLUME 397, ISSUE 10285, P1599-1601, MAY 01, 2021 Tocilizumab in COVID-19: some clarity amid controversy Shruti Gupta, David E Leaf Lancet 2021; 397: 1599-1601 Hyperactivation of the immune response, including release of pro-inflammatory cytokines such as interleukin-6 (IL-6), might play a key role in the pathophysiology of severe illness from COVID-19.1Consistent with this notion, one of the few therapies that reduces mortality in hosp...

CORRESPONDENCE|ONLINE FIRST Guidelines should not pool evidence from uncomplicated and severe COVID-19 Nicholas J White, Nathalie Strub-Wourgaft, Abul Faiz, Philippe J Guerin Lancet Published: March 22, 2021 DOI:https://doi.org/10.1016/S0140-6736(21)00469-4 The WHO Global Development Group guidelines on COVID-19 therapeutics are meant to provide evidence-based advice to all countries on the medical management of patients with COVID-19.1, 2The only smal...